Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Total revenue	$ 305,450	$ 202,566
Cost of services	111,053	112,560
Gross profit	194,397	90,006
Research and development	45,722	58,266
Selling and marketing	67,371	60,956
General and administrative	101,110	133,755
Impairment loss	0	10,402
Other operating expenses, net	3,407	7,223
Loss from operations	(23,213)	(180,596)
Non-operating (expenses) income, net
Change in fair value of warrants and contingent liabilities	(13,370)	1,170
Interest (expense) income, net	(3,032)	1,114
Other (expense) income, net	(13,014)	1,619
Total non-operating (expense) income, net	(29,416)	3,903
Loss before income taxes	(52,629)	(176,693)
Income tax benefit	343	926
Net loss	(52,286)	(175,767)
Other comprehensive income, net of tax
Unrealized gain related to available for sale securities, net	405	425
Comprehensive loss	$ (51,881)	$ (175,342)
Weighted average shares outstanding of Class A common stock, Basic (in shares)	26,891,213	24,311,989
Weighted average shares outstanding, Class A common stock of Diluted (in shares)	26,891,213	24,311,989
Basic net loss per share, Class A common stock (in dollars per share)	$ (1.94)	$ (7.23)
Diluted net loss per share, Class A common stock (in dollars per share)	$ (1.94)	$ (7.23)
Diagnostic test revenue
Total revenue	$ 302,157	$ 195,654
Other revenue
Total revenue	$ 3,293	$ 6,912
Class A common stock
Other comprehensive income, net of tax
Weighted average shares outstanding of Class A common stock, Basic (in shares)	26,891,213	24,311,989
Weighted average shares outstanding, Class A common stock of Diluted (in shares)	26,891,213	24,311,989
Basic net loss per share, Class A common stock (in dollars per share)	$ (1.94)	$ (7.23)
Diluted net loss per share, Class A common stock (in dollars per share)	$ (1.94)	$ (7.23)